Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Gains from Investment Securities (2024 - 2025)

Evommune (EVMN) has disclosed Gains from Investment Securities for 2 consecutive years, with $40502.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $40502.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $40502.0, a N/A change, with the full-year FY2025 number at $5000.0, down 89.98% from a year prior.
  • Gains from Investment Securities was $40502.0 for Q3 2025 at Evommune, down from $49902.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $49902.0 in Q4 2024 to a low of $40502.0 in Q3 2025.